LyGenesis
PrivateLast Round
Series A
Extension
Oct 24, 2023
Total Funding Raised
$37M
Company Overview
LyGenesis is a clinical-stage biotechnology company developing cell therapies that use a patient's lymph nodes as bioreactors to regrow functioning ectopic organs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
LyGenesis Comparables
Compare LyGenesis with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Satellite Bio | 81% | |
| Morphocell Technologies | 80% | |
| HepaTx Corporation | 80% |
LyGenesis Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 24, 2023 | ||||
| Convertible Debt | Dec 30, 2020 | ||||
| Convertible Debt | Oct 21, 2019 | ||||
| Series A | May 9, 2018 |
LyGenesis Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longevity Vision Fund | Convertible Debt |
| Prime Movers Lab | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 16, 2026
Monthly visitors increased 78% MoM.
- Dec 30, 2020
$11M round led by Longevity Vision Fund and Juvenescence
Recent news
Latest coverage and updates
- receives_awardJun 30, 2026
LyGenesis, Inc. received award Breakthrough T1D award on Jun 25th '26.
- receives_awardJun 29, 2026
Eric Lagasse at LyGenesis, Inc. received award research award on Jul 1st '26.
LyGenesis Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about LyGenesis's valuation, stock price, and market status.
Is LyGenesis a public or private company?
LyGenesis is a private company.
What is the current stock price of LyGenesis?
LyGenesis is a private company with no public stock price. No recent secondary market data is available.
How much is LyGenesis worth (valuation)?
Valuation information for LyGenesis is not publicly available.
Can I buy LyGenesis stock?
LyGenesis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was LyGenesis's last funding round?
LyGenesis's most recent funding round was Series A Extension on October 24, 2023.
Who are the main investors in LyGenesis?
Key investors in LyGenesis include Longevity Vision Fund, Prime Movers Lab.
Will LyGenesis IPO soon?
No public IPO plans have been announced for LyGenesis.
How can I track LyGenesis secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor LyGenesis's secondary market activity and sign up for updates.